Zhittya Genesis Medicine — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Zhittya Genesis Medicine is a clinical-stage biotech developing FGF-1, a therapeutic protein intended to induce angiogenesis (new blood vessel growth) and neurogenesis. The company's strategy targets over 75 diseases linked to poor perfusion, with active programs in neurodegenerative and cardiovascular conditions. With over 20 years and $150M in development history behind its platform, Zhittya is advancing through mid-stage trials and operates with a lean structure, leveraging partnerships for commercialization and patient logistics. Its approach offers a potentially disease-modifying treatment for chronic, underserved conditions.

CardiovascularNeurodegenerativeMetabolicVascular

Technology Platform

Recombinant human Fibroblast Growth Factor-1 (FGF-1) protein therapeutic platform designed to induce angiogenesis (new blood vessel growth) and neurogenesis to treat diseases caused by insufficient blood flow (ischemia).

Funding History

1

SeedUndisclosedUndisclosedJun 15, 2021

Opportunities

The platform potential of FGF-1 to treat over 75 ischemic diseases represents a massive opportunity, with initial targets in multi-billion dollar markets like Parkinson's (where no disease-modifying therapy exists) and diabetic wound care.

Success in ongoing trials could enable expedited pathways for 'no-option' patients and attract major pharmaceutical partnership deals for late-stage development and global commercialization.

Risk Factors

High risk of clinical failure, particularly for the novel application in neurodegenerative diseases where the angiogenesis hypothesis is not yet proven.

Significant regulatory and financing risks are present, as advancing multiple programs to approval requires substantial capital and rigorous Phase 3 data.

Competition from other regenerative and gene therapy approaches is growing.

Competitive Landscape

Zhittya operates in competitive spaces but with a distinct mechanism. In Parkinson's, it competes with symptomatic drugs (Levodopa), deep brain stimulation, and other neuro-restorative approaches (stem cells, gene therapy). In cardiovascular and wound healing, it faces competition from established devices, cell therapies, and other growth factors (e.g., VEGF). Its broad platform approach is unique but unvalidated compared to more targeted therapies.

More companies in Regenerative Medicine →More companies in United States →